Susan G. Komen®, the world's leading breast cancer organization, today announced $26 million in funding for new research projects that focus on metastatic breast cancer, developing new, more-effective treatments, and addressing disparities in breast cancer outcomes. This year's grant slate focuses on key areas that will help the organization achieve its Bold Goal to reduce the current number of breast cancer deaths in the U.S. by 50 percent by 2026.

"In order to save more lives, we must address the main cause of breast cancer deaths: metastatic breast cancer," said George Sledge, Susan G. Komen®'s co-Chief Scientific Advisor, M.D., Professor of Medicine, and Chief of the Division of Oncology in the Department of Medicine at Stanford University.

"We are pleased to be able to support research aimed at preventing breast cancers from metastasizing (spreading) and developing new, more effective treatments for metastatic disease," added Komen's coChief Scientific Advisor, Jennifer Pietenpol, Ph.D., Executive Vice President for Research at Vanderbilt University Medical Center, Director of the Vanderbilt-Ingram Cancer Center, the B.F. Byrd Jr. Professor of Molecular Oncology, and Professor of Biochemistry and Otolaryngology at Vanderbilt University School of Medicine.

More than an estimated 154,000 women in the U.S. are living with metastatic breast cancer - the most advanced stage of breast cancer that has spread outside the breast, often to the brain, bones, liver and lungs. Currently, there is no cure for metastatic breast cancer, and it is responsible for almost all the 42,000 breast cancer deaths in the U.S. each year.

Among the 60 grants Komen awarded, 38 are focused on better understanding and treating metastatic breast cancer. Grants were also given to researchers who are developing new therapies for breast cancer including aggressive subtypes such as triple negative breast cancer, investigating drug resistance, and addressing health disparities in breast cancer outcomes among specific communities.

"Breast cancer does not affect everyone equally and with the grants we're funding this year, we're moving closer to new therapies for aggressive forms of cancer, understanding why treatment doesn't work in some patients and making sure everyone has access to the care they need," said Paula Schneider, CEO, Susan G. Komen®.

Komen's 2019 portfolio includes:

60 grants totaling $25,689,384. Of these:

o 38 grants totaling $17,504,384 are focused on better understanding metastasis - why it occurs and how to prevent and treat metastatic breast cancer

o 39 grants totaling $15,579,815 for catalyzing the development of new therapies for all stages of breast cancer

o 16 grants looking into novel treatments for triple negative breast cancer

o 14 grants totaling $6,298,750 investigating drug resistance (why drugs stop working in some patients)

o 9 grants focused on disparities in breast cancer outcomes and

o 5 that apply big data technology (e.g. Artificial Intelligence, Machine Learning) to breast cancer research